Generation of Engineered Human Myocardium using myriamed myrPlates
In STAR Protocols Tibury et al. describe a robust method for the generation of engineered human myocardium (EHM) from pluripotent stem cells (PSCs) in 48 well myriamed myrPlates under defined, serum-free conditions (DOI: 10.1016/j.xpro.2020.100032).
By parallel culture of up to 48 EHM in one myrPlate, contractile heart muscle can be obtained to serve numerous applications, such as drug screening and disease modelling, which are also offered by myriamed.
The described protocol has been successfully applied to human embryonic stem cell- and induced PSC-derived cardiomyocytes, subtype-specific, i.e., atrial and ventricular, and commercially available cardiomyocyte preparations (e.g. myrCell Cardio).
To read the protocol please visit: https://bit.ly/myrPlateEHMprotocol
Separating the pharmacological wheat from the chaff is the primary goal of myriamed. Our proprietary human cell and engineered tissue models allow for the simulation of health and disease in the dish. Our platform technologies find broad applications in early stages of drug discovery and refinement of the most promising therapeutic candidates.
The availability of human cell and tissue models is transforming preclinical drug development. Applications range from early stages of lead discovery to advanced individualized phenotypic screens to shape a promising therapeutic candidate. myriamed offers a broad portfolio of highly standardized services as well as custom-made solutions to accelerate drug development.
At myriamed we focus on heart and skeletal muscle as well as on neuronal organoids. Our myrCell and myrTissue platforms define wanted and unwanted drug effects in a unique human context. myrScreen combines our expertise in phenotypic drug screens and enables deep phenotyping of drug effects on healthy or diseased human heart and skeletal muscle as well as on neuronal organoids.